# Lot No. 1

- **Source:** TED · `373008-2025`
- **Buyer:** Amgros I/S
- **Published:** 2025-06-11
- **Deadline:** —
- **Estimated value:** 1,954,865 EUR
- **CPV codes:** 33600000
- **NUTS codes:** DK011, DNK
- **Notice type:** can-standard / 29

## Description

ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 2 ml, Unit: 16 mg, Quantity in units: Denmark: 234.183, Iceland: 9.750. ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 4 ml, Unit: 16 mg, Quantity in units: Denmark: 15.640, Iceland: 10.000. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers. If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

## Award result

- **Total awarded:** 18,750,000 EUR
- **Contract concluded:** 2024-09-30
- **Winner:** Fresenius Kabi (CVR 21347809), Hameln Pharma ApS (CVR 39720213), Pfizer ApS (CVR 66351912), B. Braun Medical AS (CVR 914 113 172), Accord Healthcare A/S (CVR 556810-0258), Sandoz A/S (CVR 27744532), Baxter A/S (CVR 72246012) · value 18,750,000 EUR · 1 bids received

## Original notice

https://ted.europa.eu/da/notice/-/detail/373008-2025